Gilead’s New $250M Drug R&D Pact Adds Contenders in the Hunt for Hot Inflammation Target
MedCity News
JANUARY 12, 2025
Gilead Sciences is acquiring LEO Pharmas oral small molecule inhibitors of STAT6, a protein key to two validated inflammation pathways. Other STAT6 drug developers include Kymera Therapeutics and Sanofi-partnered Recludix Pharma, which is presenting this week during the J.P. Morgan Healthcare Conference. The post Gileads New $250M Drug R&D Pact Adds Contenders in the Hunt for Hot Inflammation Target appeared first on MedCity News.
Let's personalize your content